News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Numerate Forms Drug Discovery Collaboration with Merck & Co., Inc. (MRK) to Utilize Numerate’s In Silico Drug Design Technology


3/14/2012 8:36:14 AM

SAN BRUNO, Calif.--(BUSINESS WIRE)--Numerate, Inc., a technology platform company that is leveraging proprietary algorithms and the power of cloud computing to transform the drug design process, announced today that it has entered into a research collaboration with Merck, through a subsidiary. The collaboration will utilize Numerate’s proprietary in silico drug design technology to generate novel small molecule drug leads for an undisclosed cardiovascular disease target.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES